Fact checked by Nick Blackmer The Food and Drug Administration (FDA) has expanded its approval of a ketamine nasal spray, ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it ...

SINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best known as a horse tranquilliser or party supplement, has ...

"SPRAVATO ® is now available as a standalone treatment, meaning patients may experience improvements in depressive symptoms as early as 24 hours and at 28 days – without the need for daily oral ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Johnson & Johnson's Spravato has been approved to treat a major depressive disorder in adults who have had an inadequate response to at least two oral antidepressants, the FDA announced Tuesday.

Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...